

Index

- ability to pay 13, 325, 334, 365–7, 373, 429, 433, 440
- Abler, D. 112–13
- Aboagye, A.Q.Q. 62
- abortion and replacement decisions 150
- Abuja Goals Fund 422, 423
- access costs 342–4
 - mammographic screening 367–9
- Acharya, A.K. 283, 284–5, 287, 291
- activity-based costing (ABC) 62, 83–6
- acute appendicitis 44–5, 225, 226
- acute orbital cellulites 227
- addiction theory 346–8
- adult circumcision 416–17, 418
- advanced colorectal 222, 236
- Affordable Care Act (2010), US 387
- Africa
 - antiretroviral drugs 434–5
 - MCF country estimates 125–7, 128
 - tax administration costs 145
- age
 - in context of efficiency and equity 290–91
 - and equity 289–90
 - and price of QALY 333–4
 - relation with earnings 330
 - and VSL 329–32
- age weights 284–6, 287–9, 291, 304, 332
- aging population, MCF in context of 132–5
- ageism 289–91, 302
- Aid to Families with Dependent Children (AFDC) 237
- AIDS/HIV, *see* HIV/AIDS
- air quality regulations 336–7
- alcohol
 - Chinese consumption 112–13
 - social cost 101–3
 - as substitute/complement for marijuana 95–8, 107
 - unavoidable costs 39, 56–7
- alcohol treatment programs 164–5, 174–6, 207, 234–5
- alcohol-impaired driving 91–3
- Aldy, J.E. 328, 330–32, 336–7, 351
- Algeria, social discount rate 203
- ‘all other things are held constant’ assumption 150, 365
- allergy 324–5
- alternatives evaluation 4–5, 27
- altruism 376–7
- Alzheimer’s 222, 236
- ambulance helicopter services 376
- American Cancer Society 3–4, 21, 23
- Americans with Disabilities Act (1990) 227
- anesthesia costs/charges 85
- Andhra Pradesh, HIV-prevention interventions 50–53
- angina pectoris 76
- antenatal care, education effects 110–11
- antepartum anti-D 219
- anti-hypertensive therapy 232
- antiretroviral drugs (ARVs) 262–5, 422, 423
 - Africa 434–5
 - elderly people in US 436–8
- appendectomy 227
- Argentina, social discount rate 203
- Arnesen, T. 283, 286–7
- arrhythmias 76, 208–10
- Arrow, K.J. 300
- arthritis 217, 222, 236, 257–8
- aspirin 6, 8, 41, 63, 65, 160
- asthma 76
- asthma inhalers 222, 236
- Atif, M. 84
- Au Eong, K.G. 266
- Auriol, E. 125–7, 128, 145, 399
- Australia
 - lifetime costs of HIV study 54–6
 - MCF 130
 - mobile mammographic screening 367–9
 - price of QALYS 325–6
 - social discount rate 203
 - waiting time rationing 355
- Austria, MCF/social discount rate 130, 203
- autoimmune haemolytic anaemia 227
- Auvert, B. 165–7
- average cost per unit (AC) 33, 34, 36, 51–3, 55, 59, 66–7, 69, 73–4, 79, 86
 - use of *per diem* 63–4
 - versus marginal cost 61
- average cost-effectiveness ratio 152, 191–3
- Axnick, N.W. 104

- Baicker, K. 135–6, 137
 Baird, S. 130
 Ballard, C.L. 123–4, 125, 134, 138, 145–6, 174
 Bangladesh, social discount rate 202
 barium-enema procedure 21
 Basu, K. 110
 Bayoumi, A.M. 273–4, 278, 415
 Beaver Dam Health Outcomes Study 322
 Beck, J.R. 262
 beer quantity–frequency (Q–F) index 164–5, 175–6
 before-and-after comparisons 24–6
 Belgium MCF 130
 benefits
 components 313–14
 as cost savings 416–19
 human capital measures 315–16
 measurement 5, 6–7, 314–15
 benefits weights
 disaggregating benefits by income group 380–81
 empirical estimates 381–2
 estimates derived from economic theory 382–5
 Benin, MCF/social discount rate 128, 202
 Benoxaprophén 160–61
 beta interferon 222, 236
 better ear pure tone average (BEPTA) hearing loss 274–5
 Binagwaho, A. 416–17, 418, 423
 Birch, S. 19–20
 birth facilities
 education effects 110–11
 weighted benefits 384
 birth weights, in neonatal intensive care 230–31
 Black, L.K. 4
 Bleichrodt, H. 266–7, 268–70
 blindness 324–5
 Body Mass Index (BMI) 205–6
 Bolivia, social discount rate 202
 Bombardier, C. 267
 Boston, costs of psychiatric care 140–41
 Botswana, MCF/social discount rate 128, 203
 Boyle, M.H. 26–7, 230–31, 274
 Brazil
 Bolsa program 397
 social discount rate 203
 breast cancer
 reference requirements for treatment 44–5
 screening 232, 242, 367–9
 Brent, R.J. 7, 79–81, 124, 127, 137–9, 140–41, 142–3, 161, 163–4, 172–6, 182–3, 201–4, 258, 320, 334–5, 377, 379, 381, 383, 384, 385, 389, 390–91, 392, 397–400, 413, 414, 419, 423, 424–5, 427, 429, 431, 432, 434–5, 436, 438
 Briggs, A.H. 193, 195–9, 211, 262, 265
 bronchitis 76
 Brooklyn, drug treatment programs 344
 Brown, G.C. 271–2
 Brown, K. 21
 Browning, E.K. 399
 Browning, J.M. 399
 Buchanan, H.M. 89, 228
 budget constraints 7, 135–6, 196, 209–10, 218, 243–4, 288–9, 293
 variable 229
 burden of disease 4, 39, 57–8, 234–5, 283–4, 288–9, 304–5, 388, 434–6
 Bureau of Labor Statistics (BLS), US 328–9
 Burkina Faso
 MCF/social discount rate 128, 202
 Skilled Care Initiative 196–9
 Burrows, C. 21
 Burundi, MCF/social discount rate 128, 202
 Bush, J.W. 217, 218–19, 244, 322–3, 326
 Caesarean section 76
 Cairns, J.A. 210–11
 California, case management programs 141–3
 calorie consumption 205–6
 Cameroon, MCF/social discount rate 130, 202
 Canada
 health care evaluation practice 14–16
 MCF/social discount rate 130, 204
 neonatal intensive care 26–7
 Canning D. 435
 Cantril's ladder 308
 capability approach
 and CBA 299–300
 and CUA 295–9
 instrument for older people 297–9
 main ingredients and rationale 294–5
 and QALYs 310, 438
 and utility of restraints 305–7, 308
 CAPD 232
 Cape Verde, MCF 128
 capital costs 35–6, 37, 63–4
 capital projects 16, 26–7, 401, 403
 Carribean, HIV/AIDS 412
 Cartwright, W.S. 361, 362
 case management programs
 ‘clinical team’ program 141, 142–3, 391
 and distributional weights 389–91
 ‘intensive broker’ program 141–3, 391
 and MCF 141–3
 Program for Assertive Community Treatment 141, 142–3, 391

- cash transfers 80–81, 119, 129, 132–4, 145, 223, 299, 351–2, 390; *see also* conditional cash transfer (CCT) programs
- Central African Republic, MCF/social discount rate 128
- Central Asia, HIV/AIDS 412
- Central Europe, HIV/AIDS 412
- cervical cancer screening 176
- Chad, MCF/social discount rate 128, 202
- Chancellor J.V. 247, 262–5
- Chang, R.W. 241–3
- Chapman, R.H. 224
- charges
 - cost-to-charge ratios 69–70, 75–6, 84–5
 - distinguishing from costs 68–9
 - versus charges 68–70
- chemotherapy 78
- chest pain 76
- child health, education externalities 110–11
- childhood immunization 303, 103–6
- Chile, social discount rate 203
- China
 - cigarette/alcohol consumption 112–13
 - schistosomiasis control 108–9
 - social discount rate 202
- cholecystectomy 17–18
- cholesterol testing 232
- cholestyramine 242
- Churchill, D.N. 249–50, 251–2
- cigarette tax 199–201, 240, 347–8
- Clark R.E. 141
- Clarke, P.M. 343, 367–9, 370, 371
- Clawson, M. 342
- Claxton, K. 188
- Clemens, M.A. 23–6
- clinical outcomes, need for precise estimates 23
- clinical trials 4–5, 83, 150, 208, 365
- clozapine 56–7
- Coast, J. 296, 297–9
- cocaine, as substitute/complement for heroin 106–7
- ‘cognitive overload’ 260, 292
- cognitive services, reimbursement 76–7, 80–81
- ‘cohort effect’ 330–32
- colonic cancer tests 3–4, 21–3
- Columbia, social discount rate 203
- commercial sex workers (CSWs), HIV-prevention interventions 50–53, 431–2
- commitment mechanisms 205–6
- common unit of effect 131
- common unit of measurement 218
- communicable diseases 53, 113, 288–9
- community preferences 223, 227, 249–50, 345
- community psychiatric care
 - benefits 326–7
 - case management programs 141–3
 - and MCF 139–43
- comparison programs 233, 242
- compensation tests 385–6
 - and economic efficiency 340–41
- compensation, WTA 348–52
- competitive markets and costs 64–6, 76–9
- complements 95–8, 106–7, 112–13
- compliance effects, worksite treatment 19–20
- conditional cash transfer (CCT) programs 379, 389, 398, 405, 421–2
 - evaluating in SSA 400
 - evaluating targeting 399–400
 - Kenya 397–400
 - Sub-Saharan Africa 400
- condoms 53–4, 161
 - social marketing (CSM) programs 426–8
- confidence interval (CI) 181, 189–93, 201, 207–11, 230, 251
 - Bonferroni method 194
 - exact method 194–5
 - rectangular method 193–4
- Congo Democratic Republic, MCF, social discount rate 128, 202
- Congo Republic, MCF 128
- conjoint analysis (CA) 341, 342, 365–7, 410
- Conley, B.C. 317, 319–20
- consistency of choice 184, 186, 188
- constant returns to scale 19–20, 37, 73, 78–9, 86, 151
- constitutional decision-making contexts 227–9
- construct validity 252, 276, 278, 415
- consumer sovereignty 13, 16, 27, 89, 250, 328, 329, 340, 377
 - full or zero acceptance 345
 - as information problem 103
 - partial acceptance in CBA 346–8
 - violating 358–63
- consumer surplus 75, 93, 101–3, 114, 299, 324–5, 426–8
 - in presence of addiction 346–8
- contingent valuation (CV) 322–3, 341, 342, 344, 347, 357, 363–5, 369, 370, 381, 391, 399, 410
- continuous ambulatory peritoneal dialysis 219
- control groups 25, 156, 157, 160, 168, 189–91
- controlled clinical trials 4–5, 83, 150, 208, 365; *see also* randomised controlled trials (RCTs)
- Cook, J. 17–18
- Cookson, R. 295, 296, 299, 374
- Copenhagen Consensus Centre, *RethinkHIV* project 420–24, 435
 - expert economist panel outcomes 421–2
 - coronary bypass 78, 219, 241–2

- cost allocation 62–3
- cost centers 85
- cost minimization (CM)
 - applications 44–56
 - and CBA 40–41
 - as CBA 41–2
 - and CEA 42–3
 - and cost standardization 70–73
 - and economic theory 33–9
 - fundamental weaknesses 75
 - method 8–9
 - problems 47–8, 56–8
 - pros and cons 46–7, 51–3, 417–19
 - usage 14–15
- cost shifting 119, 136–41
- cost standardization 70–73, 75, 81
- cost-benefit analysis (CBA) 40–41
 - alternatives to 11–12
 - applications 14–26, 326–36
 - and capability approach 299–300
 - CEA as 9–10
 - converting CUA into 320–26
 - efficiency costs and benefits 13
 - equal weights problem 378–9
 - method 6–7
 - methods for converting CEA into 161–5, 169
 - role of MCF 115–17
 - social perspective 12
 - usage 14–15, 132
 - and utility values 250
 - versus CUA 227–9
 - see also* equity
- cost-effectiveness acceptability curves (CEAC) 195–9, 220–21
- cost-effectiveness analysis (CEA)
 - applications 165–76
 - as approach to evaluation 149
 - basic principles 151–6
 - as CBA 9–10
 - and CM 42–3
 - costs to include 149–50
 - discounting 181–8
 - discounting of benefits 184–6
 - effects to include 150–51
 - estimating effects using RCTs 156–61
 - general comparability to CUA 218
 - hypertension programs 19–20
 - and MCF variance by project 131–2
 - method 7–8
 - methods for converting into CBA 161–5, 169
 - problems 43, 176–7
 - and public-private partnerships 132
 - social perspective 12–13
 - uncertainty and sampling error 188–99
 - usage 14–15, 131
 - versus CUA 217–18
- cost-effectiveness model 151–3
 - hypothetical example 152
 - hypothetical example with competing choices 153
- cost-effectiveness ratios
 - calculating and interpreting 153–6
 - calculating confidence intervals 193–5
 - delayed programs 186–7
 - estimate of cut-off ratio for hypothetical serious disease 170–72
 - MCF as cut-off ratio 163–4
 - sampling error 191–3
 - utility of income as cut-off ratio 162–3
 - see also* average cost-benefit ratio; incremental cost-benefit ratio (ICER)
- cost-effectiveness, interpretations of 176
- cost-to-charge ratios (RCCs) 69–70, 75–6, 84–5
- cost-utility analysis (CUA)
 - applications 229–43
 - basic principles 222–7
 - and capability approach 295–9
 - converting into CBA 320–26
 - equity in 281–2
 - as generally comparable CEA 218
 - method 8
 - problems 243–4
 - in priority setting 225–7
 - QALY weights 295–9, 374–6
 - threshold as range of values 220–22
 - usage 14–15
 - utility values 249–50
 - versus CBA 227–9
 - versus CEA 217–18
 - weighted criterion 377–80
 - see also* equity; utilities measurement
- cost-utility league tables 218–19, 224
 - assessment 231–3, 253–4
 - comparative results for selected programs 218–19
 - importing tables from another country 243–4
- Costa Rica, social discount rate 203
- costs
 - applications 73–83
 - definition 31
 - distinguishing from charges 68–9
 - long and short runs 32
 - long run cost curves 35–7
 - marginal versus average 61
 - and markets 64–8

- by modality 71–2, 80–82
- overhead and joint 61–3
- problems 83–5
- proportional relationship with outcomes 23
- sampling error 188–93
- versus charges 68–70
- Côte d'Ivoire, MCF/social discount rate 128, 202
- counterfactual outcomes 156–8
- counting fingers (CF) test 271
- Cox II (routine) 222, 236
- Craig, B.M. 248
- Cretin, S.B. 186, 187
- croup syndrome 227
- Cullis, J.G. 356–7
- Culyer, A.J. 66
- cure 98–100
 - versus prevention 101, 107–9
- Cutler, D. 205
- cytology 222, 235, 236
- Dageforde, L.A. 45–8
- Danish hospitals, economies of scope 74–5
- data sources 15
- deafness 283–4
- Deaton, A. 156, 158, 159–60, 161, 169–70
- dementia 305–7, 308
- Demonbynes, G. 23–6
- Denmark
 - MCF/social discount rate 130, 204
 - valuing a QALY 332–4
- dental caps 226, 237, 292, 387
- depression 436–8
- developing countries, estimating VSL 430–31
- Devlin, N. 220–22, 234–7, 388
- diagnostic related groups (DRGs) 48, 86–7
 - costing and evaluating 70, 75–6
- Dickey, B. 140–41
- 'difference in difference' (DID) estimator 25
 - compared to RCTs 156–8
- direct cost–benefits 5, 17, 19–20
- direct demand 341
- direct utility approach
 - antiretroviral drugs 436–7
 - pros and cons 438
- disability adjusted life year (DALY) 169, 282
 - criticism of 286–7
 - and equity 284–7
 - and global burden of AIDS 304–5
 - measuring 287–8
 - in measuring global burden of disease 288–9
 - and QALYS 283–4
 - and sleeping sickness treatments 302–4
 - use for HIV 438–9
- disability classes/weights 253–4, 284, 286–8
- discounting
 - clozapine treatment 56–7
 - country estimates of social discount rates 201–4
 - discounting benefits in CEA 184–7
 - hyperbolic discounting and obesity 204–6
 - individual discount rates in industry
 - employment choice 199–201
 - lifetime disease 53–6
 - rate of discount and economic theory 181–3
 - rate of discount and hyperbolic discounting 183–4
 - recommended discount rates 187–8
 - survey of individual discount rates 210–11
 - in UK studies 233
 - when to use 180
- disseminated candidiasis 227
- distribution weights
 - and benefits of eliminating arthritis 391–2
 - deriving numbers weights from PTO of ability to walk freely 392–5
 - determining 381–5
 - disaggregating total benefits by income group 380–81
 - evaluation of CCT programs for OVC 397–400
 - evaluation of user fees 395–7
 - and mental health care management programs 389–91
 - numbers weights 385–8
 - problems 401–3
- doctor valuations 249–50
- Dolan, P. 259–62, 292, 376, 387
- Dolders, M.G.T. 250
- dominated strategies 47, 208, 224, 244
- Dominican Republic, social discount rate 202
- Donaldson, C. 363–5, 376, 384
- Doubilet, P. 176
- Dowie, J. 380
- Dranove, D. 62
- Drug Abuse Treatment Cost Analysis Program (DATCAP)
 - costs by modality 71–2
 - data collection system for substance abuse programmes 72, 80–82
- drug administration 62
- drug evaluations, numbers of 14–15
- drug status switching 358–60
- drug treatment programs 344, 360–63
 - external benefits 382
 - treatment gap 362
 - WTP 314–15
- Drummond, M.F. 5, 16, 150, 187–8, 217–18, 231–3, 241–2, 245, 249, 251, 253
- Dunn, D.L. 77

- Eastern Europe, HIV/AIDS 412
- ECG costs/charges 85
- economic evaluation
- components 5
 - definition of 4-5
 - need for 3-4
 - types 6-9
 - and uncertainty 180-81
- economic outcomes, need for precise estimates 23
- economic theory
- and CM 33-9
 - and discount rate 181-3
 - distribution weights derived from 382-3
- economies of scale 37, 49, 62, 73-5, 99
- economies of scope 63, 73-5, 78
- ectopic pregnancy 226, 227, 237, 292, 387
- Ecuador, social discount rate 203
- Eddy, D.M. 224-5, 237-9, 243, 292, 387
- education
- and CCT programs 398, 400
 - delivery modes 177
 - demand 169-70
 - female education and HIV 161, 424-5
 - and infant mortality 88
 - and intestinal worms 168-70
 - and maternal and child health 110-11
 - web-based delivery 177
- effect mechanisms, evaluation 161
- effectiveness, measurement 5, 7-8
- efficiency 11
- age in context of 290-91
 - combining with equity 379-80, 383-4
 - conflict with equity 291-2
 - costs and benefits 13
 - and DALYs 309
 - pure efficiency 220-21
 - and QALYs 309, 321, 388
 - trade-off with equity 290-94
 - and WTP 340-41, 372
- efficiency-based compensation tests 340-41, 385-6
- eflornithine 302-4
- Egypt, social discount rate 202
- El Salvador, social discount rate 203
- Elamin, E.I. 84
- elderly people
- arthritis treatments 160-66
 - ARVs 436-8
 - capability instrument 297-9, 305-7, 308
 - disease types 288
 - health insurance 48, 76-7, 132, 140
 - noncommunicable diseases 288
 - nursing home versus hospital care 349, 363-5
 - in psychogeriatric wards 305-8
 - QALY weights 382
 - senior companion program 370
 - time costs 81-3
 - utility scores 276
 - VSL 331, 336-7
 - WTP 357-8, 354, 373
 - see also* age and equity; ageism
- elective surgery, waiting times 353-5
- electro-physiology-guided drug therapy (EP) 208-10
- Elixhauser, A. 14
- endowment effects 350, 351-2
- Environmental Protection Agency (EPA), US 328
- 'Clear Skies' initiative 336-7
- Epstein, J.F. 361-2
- Equatorial Guinea, MCF 128
- equity
- age and 289-90
 - age in context of efficiency and 290-91
 - applications 300-307, 388-400
 - capability approach 294-300
 - in CUA 281-2, 374-6
 - and DALYs 283-9
 - person trade off approach 291-4
 - problems 307-8, 401-3
 - and rationing 354-5
 - role of QALY weights 13, 282-3
 - trade-off with efficiency 290-94
 - weighted cost-benefit criterion 377-80
- equity weights 385-8
- as externality 376-7
- Eritrea, MCF 128
- erythropoietin treatment 232
- estrogen therapy 217, 219, 252-3
- ethical dilemmas 303
- Ethiopia, MCF/social discount rate 128, 202
- European Union, weighting system 384
- EuroQoL
- (EQ-5D) 248, 258-62, 274-7, 296, 306-7, 308, 333
 - five-level EQ-5D (EQ-5D-5L) 259
 - and NICE 262
 - questionnaire 258, 259
 - utility weights 259-62
 - valuation of health states 261
 - visual analogue scale (EQ VAS) 258-9
 - youth version (EQ-5D-Y) 258
- evaluative management (EM) services 79
- excise tax 95, 119-20
- expected utility 256-7, 263, 279, 338, 349
- expert opinion 15, 209, 223-4, 240-43, 296, 361-2, 421-2

- explicit preferences 309, 341, 381–2
 exponential discounting 183
 export tax 125, 127
 external benefits 314–15, 428–9
 ARVs 423
 complements and substitutes 98
 condoms 428
 drug treatment programs 314, 377, 382
 education 111
 immunization programs 93–5
 external costs
 applications 101–11
 and interdependent markets 95–8
 and markets 91–5
 over time 98–101
 problems 111–13
 social costs and private costs 89
 threshold values as switching values 90–91
 external validity 160–61, 166–7, 178
 externalities
 defining 88–9
 equity weights as 376–7
 internalizing 93
 extracorporeal shock wave lithotripsy (ESWL)
 17

 face-to-face education delivery 177
 factor tax 125, 127
 'fair innings' argument 290, 382
 family planning 424, 428
 Feeny, D. 218–19
 Feigenbaum, B. 355–6
 final effects 151
 Fingarette, H. 174
 Finkler, S.A. 68–9, 84–5
 Finland, social discount rate 204
 fixed budget constraints 150, 151–3, 156, 172,
 178, 192, 239–40, 310, 421, 435–6, 443
 and program ranking 228–9
 fixed costs 32, 33–6, 48–9, 50–51, 53–4, 64
 average fixed costs 34–5
 fixed prices 35, 65–6, 421, 423–4, 439–40
 Flynn, T.N. 297
 for-profit hospitals, privatization change
 138–9
 Forester, T.H. 334–5
 Foster, J.E. 110
 France, MCF/social discount rate 130, 203
 Frank, R.G. 56, 57
 French, M.T. 71, 72–3, 82–3, 254
 Fryback, D.G. 322
 Fukui, T. 415
 functional ability, numbers weights 392–5
 funding sources 15
 future health care spending and MCF 135–6

 Gabon, MCF/social discount rate 128, 203
 Gafni, A. 257
 gallstone treatments 17–18
 Gambia, MCF 128
 Garbacz, C. 370
 Garber, A.M. 162–3, 170–72, 219, 244, 318,
 336, 338, 426, 441
 Gardiner, J. 193, 208–10
 GDP
 per capita 219, 430–31, 434–5
 share of health care spending 135–6
 gemcitabine 222, 236
 general practitioners (GPs) 232, 233, 369
 Gerard, K. 243–4
 Gerdtham, U.-G. 301, 382
 Germany, MCF/social discount rate 130, 204
 Gertler, P.J. 380–81, 395–7, 401, 402
 Getzen, T.E. 23
 Ghana Health Assessment Project Team 304
 Ghana, MCF/social discount rate 128, 202
 GI disorders 76
 Glaeser, E. 205
 global burden of AIDS 304–5
 global burden of disease 288–9
 Global Fund to Fight AIDS, TB and Malaria
 (GFATM) 434–6
 globalization of evaluations 15–16
 glycoprotein 222, 236
 GNP 299
 'gold standard' 70, 77, 158, 161, 178, 256
 Gold, M.R. 150, 188, 223
 government intervention 11
 Gray, A.M. 193
 Greece, social discount rate 203
 Gregor, D.H. 21, 23
 Green, C. 292
 Greensboro, drug treatment programs 344
 Grewal, I. 297
 Grfeorer, J.C. 361–2
 Grob, G.N. 139
 Gruber, J. 346–8
 Grutters, J.P.C. 274–7
 Guatemala, social discount rate 202
 Guinea Bissau, MCF 128
 Guinea, MCF 128
 Guinness, L. 50–53
 Gyrd-Hansen, D. 332–4, 341, 433, 441

 Haacker, M. 431
 Hadley, J. 78, 79
 Hadorn, D.C. 226
 Haiti, social discount rate 202
 hand motion (HM) test 271
 hand-assisted laparoscopic donor nephrectomy
 (HALDN) 46–7

- Hannum, R.J. 93, 94, 101, 103–6
 Harberger, A. 383–4, 385
 Hargreaves, J.R. 161
 Harper, D.R. 44–5
 Harris, J. 290
 Hauber, A.B. 257
 headaches 6–7, 8, 41, 76, 293
 Heal, G.M. 184
 health and safety 327–9, 350–51
 health care evaluation practice, survey of 14–17
 health care professions
 education delivery modes 177
 valuations 249–50
 Health Services Commission, Oregon 226–7, 239–41
 health states
 applications 265–77
 duration 248, 277
 identifying and describing 247–8
 measurement methods 255–66
 measurement sources 252–5
 statistical accuracy of methods 250–52
 two-dimensional listing 253–4
 utility values 248–50, 233
 health systems, strengthening 422, 423
 Health Utility Index 2 (HUI 2) 262, 274–7
 healthy life year (HeaLY) 304–5
 healthy-years equivalent (HYE) 257–8
 hearing aids 274–7
 heart failure 76
 heart transplants 232
 Hellinger, F.J. 55–6
 helminthic diseases 303
 hemodialysis 249–50, 251–2
 hepatitis B 254
 hernia 227
 heroin, cocaine as substitute/complement for cocaine 106–7
 Hinman, A.R. 104
 Hirth, R.A. 322–4, 332, 333, 338
 HIV/AIDS
 AIDS defining illnesses (ADIs) 273
 antiretroviral drugs 262–5, 422–3, 434–8
 benefits as cost savings 416–19
 blood screening 303
 CCT programs 397, 400
 costs in terminal stages 55–6
 country phases 411
 DALYs 286
 difficulty of treating without CBA 413–14
 direct utility approach 436–8
 and female education 161
 global burden of 304–5
 human capital approach 424–6
 human choice element 413
 individual phases 410–11
 infection utilities 273–4
 lifetime costs 53–6
 and male circumcision 161, 165–7
 market demand curves 426–9
 means of infection 411
 mother to child transmission (MTCT) 411, 422, 423, 424
 number of possible interventions 414
 paradoxes 413
 prevalence and incidence numbers 411–12
 pricing a QALY 419–24
 priority setting 420–23
 problems 438–40
 and QoL 277–8
 revealed preference method 433–6
 scaling up prevention interventions 50–53
 testing 166–7, 431–2
 transmission by discordant couples 431–2
 utility value for QALYs 414–15
 vaccine research and development 422
 voluntary counselling and testing (VCT) 431–2
 VSL approach 429–33
 Hoch, J.S. 197–8
 Hochman, H.M. 389–90
 Hoffman, V. 351–2
 home dialysis 232, 248–9, 251–2
 Honduras, social discount rate 202
 Hong Kong, social discount rate 203
 horizontal equity 281–2, 284–5
 Horngren, C.T. 62
 Horowitz, J.K. 350
 Horsman, T. 274, 275
 hospital care versus nursing homes 363–5
 hospital construction expenditures 401, 403
 hospital costs
 cirrhosis of the liver 57–8
 clozapine treatments 56–7
 DRG categories 75–6
 estimating 73–5
 gallstone treatments 18
 knee arthroplasty 34–7, 48–50, 73–5
 use of *per diem* 63–4
 versus community care 139–43
 see also length of stay (LOS)
 hospital dialysis 219, 232, 248–9, 251–2
 'hotel costs' 64
 Hounton, S. 196–9
 household income groups, MCF estimates by 135–6
 Hsiao, W.C. 77–9
 Hu, T.-W. 141–2, 143
 Hughes, J. 365–7

- Hull, R. 64
- human capital approach 13, 27–8, 169, 217, 219, 231, 354
- HIV/AIDS 424–5
- measures of benefits 315–16
- and mental health 316–17
- problems 336–7
- pros and cons in use for HIV/AIDS 425–6
- relation with WTP 317–19
- using time as numeraire 320–21
- human development index (HDI) 299
- hunger and HIV/AIDS 414
- Hurley, S. 54–6
- Hyder, A.A. 304–5
- hydrochlorothiazide 242
- hyperbolic discounting 183–4
- and obesity 204–6
- ‘time inconsistency problem’ 346
- hypertension 19–20, 150, 153–6, 180, 219, 252, 360
- hysterectomy 76
- immunization programs
- and consumer sovereignty 345
- education effects 110–11
- external benefits 93–4
- HIV/AIDS 422
- Japanese encephalitis 111–12
- Kenya 169
- meningitis 90–91
- over-provision 94–5
- social costs 103–6
- implantable cardioverter defibrillators (ICDs) 208–10, 211
- implicit markets 315
- in vitro* fertilization 366–7
- in-kind transfers 80–81, 82, 351–2, 389–91, 444
- ‘incentive compatibility problem’ 12
- income groups
- disaggregating total benefits by 380–81
- taxation by 135–6
- income growth and social discount rates 201–4
- income tax 124–5, 126–7, 128–9, 131–6
- income weights 382, 389–91, 397
- incremental cost–effectiveness ratio (ICER)
- 10, 14, 27, 47, 152–3, 155, 195–9, 209–10, 235–7, 276
- NICE decisions ranked by 221–2
- sleeping sickness 302–4
- upper and lower bounds 191–5
- ‘independence of irrelevant alternatives’ axiom 300
- India
- HIV/AIDS 304–5
- social discount rate 202
- indifference curve 104, 302, 313–14, 318–19, 353, 436
- indirect cost–benefits 5, 13, 17–18
- individual preferences 5, 13, 16, 27–8, 89, 162, 240–41, 249–50, 271, 282, 316–17, 345, 358–60, 365–7, 426
- externalities 376–7
- Indonesia, social discount rate 202
- inequality, societal aversion to 182–3, 212, 283, 383
- infant circumcision 416–18, 423
- infant mortality and education 88
- informal sector 125, 127
- information deficiencies 50, 90, 103–4, 114, 181, 249, 250, 315, 340, 358, 360
- inguinal hernia, reference requirements for treatment 44–5
- injecting drug users (IDUs) 411, 439
- inpatient modalities, costs by 72, 82–3
- inpatient programs, mental health 172–4, 326–7
- insecticide-treated net (ITN) 24–6, 156
- reselling 351–2
- Institute for Health Metrics and Evaluation 288–9, 305
- insurance 68–9, 76–7, 79, 80–81, 86–7, 132, 135, 140, 226, 229, 238–40, 369, 387
- intangible cost–benefits 5, 19–20, 89
- adjusting market prices to measure 314–15
- use of implicit markets to measure 315
- use of similar markets to measure 314
- integrated rural development (IRD) projects 23–6
- inter-temporal choices 181–2, 201, 212
- interdependent markets 106–7
- effects on individuals doing purchasing 95–7
- effect on individuals not doing purchasing
- intergenerational equity 166, 182–3, 184–5
- internal consistency 251
- internal validity 160, 166
- interval estimates 180–81
- intestinal worms programs 130, 160, 168–70
- intra-generational discount rate 184
- Investigating Choice Experiments for the Preferences of Older People (ICECAP-O)
- 297–9, 305–7, 308
- attributes to include 297
- utilities of attributes 297–8
- Iran, social discount rate 203
- Ireland, social discount rate 203
- Israel
- health care priority setting bodies 240
- social discount rate 203
- Italy, MCF/social discount rate 130, 203

- Jamaica
 PATH program 397
 social discount rate 203
- Japan
 female life expectancy 285
 MCF/social discount rate 130, 204
 price of QALYS 325–6
- Japanese encephalitis (JE) 111–12
- Jari, J. 39, 57, 58
- Jerrell, J.M. 141–2, 143
- job risk 199–201, 327–9, 350–51
- Jofre-Bonet, M. 106–7
- Johannesson, M. 266–7, 268–70, 301, 376, 382
- Johannesson, P.O. 301–2
- Johar, M.A. 355
- joint costs 61–3, 74, 84–5
- joint procedures 76
- Jones, P.G. 356–7
- Kahneman, D. 350
- Kaplan, R.M. 217, 218–19, 224, 226, 227, 244, 246, 250, 266, 277, 322–3, 326
- Keeler, E.B. 186, 187
- Kenya
 bednet usage 24–6, 156
 conditional cash transfer programs 397–400
 intestinal worms program 130, 168–70
 male circumcision 161
 MCF/social discount rate 128, 202
 vaccination programs 169
- Khandker, S.R. 156–8
- kidney dialysis 248, 249–50, 251–2
- kidney transplants 16, 232, 250
- Kind, P. 233, 253–4, 255, 266, 292
- Klarman, H.E. 217, 314
- Klevit, H.D. 226, 227
- knee arthroplasty, hospital costs 34–7, 48–50, 64
- knee conditions 232, 241–3, 292–4
- Kniesner, T.J. 350–51
- Koplan, J.P. 104
- Kremer, M. 168–70, 413
- Kristensen, T. 74–5
- Kuklys, W. 294, 295, 299
- Kunshan Country, China, schistomomiasis, control 108–9
- Kuwait, social discount rate 203
- laboratory costs/charges 48–50, 85
- laparoscope hernia 222, 236
- laparoscopic cholecystectomy 17–18
- laparoscopic donor nephrectomy (LDN) 46–7
- labour costs 34–5, 62, 83–4
- labour market choice 350–51
- and individual discount rates 199–201
 and VSL 327–9
- Lasker, E.M. 193
- law enforcement costs 326–7
- law of diminishing returns 34–7, 66, 437–8
- length of stay (LOS) 35, 36, 48–50
 substance abuse programs 72–3
- Lesotho, social discount rate 202
- Libya, social discount rate 203
- Lie, R.K. 161, 240
- life expectancy
 and cervical cancer 176
 and cirrhosis of the liver 57, 58
 and estrogen use 252–3
 and monotherapy 263–5
 QALY valuation 283–90, 322–4
 rates 12, 182–3
 and social discount rates 201–4
 and speed limits 334–6
- life expectancy discount rate (LEDR) 169, 182–3
- lifetime costs
 diastolic blood pressure 360
 HIV 53–6
 MC interventions 416–17
 THA/osteoarthritis 241
- lifetime earnings 217, 230, 319–20, 316–17, 319–20, 335
 in HIV interventions 424–6, 431
 relation with WTP 320
 and VSL 329–32
- 'like as like' principle 285
- Lin, T.H. 277–8, 414–15
- Lindelow, M. 110–11
- Lindsey, C.M. 355–6
- Linnerooth, J. 317–19, 336, 338
- live donor kidney transplants, costs 45–8
- liver cirrhosis 39, 57–8
- Llewellyn-Thomas, H. 267, 277
- lobectomy 78
- Logan, A.G. 19, 20, 153–6, 180
- logical consistency 184–6, 256
- logistical regression 301–2
- Lomborg, B. 420–22
- long run cost curves 35–7
- long run costs 32
- long-term health effects 180, 188, 205
 CCT programs 398–400
 and discounting 180
- Lopez, A.D. 283
- Lorgelly, P. 310
- loss aversion 350
- McCollister, K.E. 80–82
- McConnell, K.E. 350

- Madagascar, MCF/social discount rate 128, 202
- Mainardi, S. 401, 403
- maintenance costs 141–3
- Makai, P. 305–7, 308
- Malawi
MCF/social discount rate 128, 202
Zomba program 397
- Malaysia, social discount rate 203
- male circumcision (ML) programs 161, 165–7, 422–3
Rwanda 416–17
- males having sex with males (MSM) 411
- Mali, MCF/social discount rate 128, 202
- Maloney, S. 177
- marginal benefits (MB) 40–43
in a dynamic context 98–100
- marginal cost of public funds (MCF)
African countries estimates 125–7
applications 132–43
calculating under constant costs 120
calculating under perfectly elastic demand 121
calculating when tax rates increase 123
CEA with variance by project 131–2
as cut-off ratio 163–4
and economic theory 119–23
method for calculating 127–9
possibility of revenue neutrality 129–30
problems 143–5
role in CBA 115–17
special role in health care evaluations 117–19
US Federal estimates 123–4
US state estimates 124–5
under different scenarios 137
using household income ratios 130
variance with tax rate 125–7, 143–4
- marginal costs (MC) 40–43
in a dynamic context 98–100
versus average costs 61
- marginal product (MP) 315–16
- marginal rate of substitution 318, 436
- marginal revenue product 424
- marginal tax rate (mtr) 135–7
- marginal utility (MU) 64–6, 170–72, 228–9, 318, 348–50, 381–5, 387, 433
- marijuana, alcohol as substitute/complement 95–8, 107
- market choice 327–9, 373
- market equilibrium 64–7, 88, 91–2, 101, 103–6, 428
- market mechanism 11
- market prices 91–2, 181, 356–7, 427
absence of 341
and ability to pay 429
adjusting 314–15
competitive markets 64–6
to measure costs 223–4
non-competitive markets 66–8
and WTP 352
- market-based WTP approach 426–8
pros and cons 428–9
- markets
and costs 64–8
and external costs 91–8
- Markov modelling
Markov cohort simulation 263–5
Markov process 263
- Martin, S. 341, 353–5
- Mason, H. 323–4, 333
- Massachusetts, psychiatric care 40–41
- maternal health, education externalities 110–11
- Mauritania, MCF/social discount rate 128, 202
- Mauritius, social discount rate 203
- Maynard, A. 231
- Meals on Wheels programs 297
- measles vaccinations 104–5
- Medicaid 135, 225, 226–7, 237–41, 387
- medical/surgical supply costs/charges 85
- Medicare 48, 76–9, 80, 81, 132, 135, 141, 208–9
- Mehrez, A. 257
- melarsoprol 302–4
- Meltzer, H.Y. 56
- meningitis 227
- meningitis vaccination 90–91
- meningococemia 227
- mental health
alternative treatments 326–7
case management programs 141–3, 389–91
and human capital approach 316–17
- methadone maintenance programs, costs 72–3, 82
- methylphenidate 222, 236
- Mexico
HIV/AIDS vaccines 439–40
Progreso program 379, 397–8, 400
social discount rate 203
- Middle East, HIV/AIDS 304–5, 412
- Miguel, E. 168–70
- Millennium Villages Project (MVP) 23–6, 27
- Miller, F.G. 161
- Miller, T.R. 430–31
- miscarriage management 365–7
- Mishan, E.J. 95, 97, 316
- mobile breast cancer screening 367–9
- monopoly 62, 67–8, 86, 138
- Mooney, G. 243–4
- Moore, M.A. 184
- Moore, M.J. 199–201, 327–9

- Morgenstern, O. 256
 Morimoto, T. 415
 Morocco, social discount rate 202
 Morrow, R.H. 304–5
 Mozambique
 education externalities 110–11
 MCF 128
 Mullainathan, S. 347–8
 mumps vaccinations 104–5
 Murray, C.J.L. 283, 284–5, 287, 291
 Musgrove, P. 90–91
 mutually exclusive programs 9–10, 47, 152–3, 155, 193, 363
- Namibia, MCF 128
 National AIDS Commission, Rwanda 416
 National Alcoholism Program Information System (NAPIS) 175
 National Health Service (NHS), UK 9–10, 15, 131, 240, 343, 353–5, 363–5
 National Highway Safety Administration, US 91
 National Institute for Health and Clinical Excellence (NICE), UK 10, 296
 discount rate guidelines 188
 and EuroQol 262, 274
 non-use of MCF in 130–32
 public appeals process 240
 technology decisions 10, 220–22, 233–7, 388
 National Traumatic Occupational Fatality (NTOF) project, US 328–9
 Natrass, N. 423
 need, definitions of 291
 neonatal intensive care 26–7, 218, 219, 230–31
 Nepal, social discount rate 202
 net benefit (NB) framework 195–9, 363–5
 Netherlands
 hearing aid interventions 274–7
 MCF/social discount rate 130
 nursing homes 305–7, 308
 Neuhauser, D. 21–3
 neurosurgery 232
 New York City, ARVs for elderly people 436–8
 New Zealand
 health care priority setting bodies 240
 social discount rate 203
 newborns, standard versus maternal care 196–9
 Newlands, D. 196–7, 199
 Niger, MCF/social discount rate 128, 202
 Nigeria, MCF/social discount rate 128, 202
 no light perception (NLP) test 271
 no-program alternative 152–3, 154–6, 174, 235, 242
 non-communicable diseases 288–9
 non-competitive markets and costs 66–8, 79
 non-experimental studies 156, 161, 166
 non-federal general hospitals (NFGHs), net benefits of privatization 137–9
 non-health functionings 297, 301–2, 310, 371–2, 438, 441
 non-Hodgkin's lymphoma 227
 non-market constraints 295
 non-parametric method (NP) 301–2
 non-profit sector 68–9
 net benefits of privatization change 138–9
 non-small cell lung 222, 236
 nondrug evaluations, numbers of 14–15
 Nord, E. 255, 266, 267, 277, 283, 286–7, 291–2, 375, 380, 386–7, 392–5
 North Africa, HIV/AIDS 412
 North America, HIV/AIDS 412
 Norway, MCF/social discount rate 130, 304
 nuclear medicine, costs/charges 85
 numbers weights
 and access 387
 from PTO of ability to walk freely 392–5
 and NICE 388
 numbers as third social objective 385–6
 nurse valuations 249–50
 nursing costs 19–20, 34–7, 48–9, 62, 154
 and PTOs 386–7, 392–5
 nursing homes
 use of restraints 305–7, 308
 versus hospital care 363–5
 nutrition 180, 186, 204–6, 288, 294–5, 300
- O'Brien, B.J. 191, 193, 195–9, 211, 350
 obesity 182, 204–6
 Office of Management and Budget (OMB), US 315
 Olsen, J.A. 300–301, 307–8, 376
 Oman, social discount rate 203
 open cholecystectomy 17–18
 open donor nephrectomy (ODN) 46–7
 operating costs/charges 34–6, 48–50, 64, 85
 opportunity costs 31, 33, 44–5, 68–70, 75, 77, 163–4, 169, 223–4, 353, 355, 357–8, 416
 option value 376–7
 Oregon plan 225, 226–7, 237–41, 387
 criticisms 243
 expected effect on number of people covered, services covered and financial costs 238
 top ten priorities 227
 Organization for Economic Co-operation and Development (OECD) 285
 orlistat 222, 236
 'orphan' treatments 235

- orphans and vulnerable children (OVCs) 397–400
- Oster, E. 413, 414
- outpatient modalities, costs by 71–2, 82
- outpatient treatments 16, 56, 73–4
 Danish hospitals 74–5, 86
 time costs 81–3
- outputs, proportional relationship with costs 23
- over the counter (OTC) drugs 358–60
- overhead costs 61–3
- Overlander, J. 239–40
- pacemaker implantation 232
- Pakistan, social discount rate 202
- Panama, social discount rate 203
- Pap smear tests 176
- Papua New Guinea, social discount rate 202
- Paraguay, social discount rate 203
- paralysis, WTP per QALY 324–5
- Paretian tax 93
- Pareto efficiency 363
- Pareto improvement 340–41, 385–6
- Parkin, D. 220–22, 234–7, 388
- partial equilibrium analysis 16
- Patel, M. 80–81
- Patrick, D.L. 291
- Pauly, M.V. 227, 228, 229
- Peabody, J.W. 286
- Penang, X-ray labour costs 83–4
- peptic ulcer, reference requirements for treatment 44–5
- per diem* costs 63–4
- peritoneal dialysis 249–50, 251–2
- peritonitis 227
- person trade-off (PTO) approach 282, 287, 307–8, 375–6
 ability to walk freely 392–5
 decomposing 292–4
 estimation of weights 300–301
 numbers effect 386–7
 rationale for 291–4
- person-service units (PSUs) 238–9
- personal characteristics 16, 150, 159, 166, 170, 285, 295, 309, 327
- pertussis vaccinations 104–5
- Peru
 social discount rate 203
 user fees 395–7, 401
- Peto, R. 160
- Petry, N.M. 106–7
- pharmacy costs/charges 48–50, 85
- Phelps, C.E. 91, 101–3, 104, 105, 106, 162–3, 170–72, 219, 244, 318, 336, 338, 426, 441
- phenylketonuria 227
- Philippines, social discount rate 202
- Philipson, T. 413
- physical therapy costs/charges 85
- physician services
 share of bills counting as costs 81
 social value 79–81
 use of RBRVS to value 76–9
- Pigou, A.C. 88, 181
- Pisani, E. 413
- Pizer, S.D. 357–8
- PKU screening 219
- plastic surgeons, social value of services 79–81
- pneumonia 227
- pneumonia vaccines 217
- Poland, MCF 130
- poliomyelitis vaccinations 104–5
- Politi, C. 287, 288, 302–4
- Population Services International (PSI) 427
- Portugal, social discount rate 203
- Posner, R. 413
- postpartum anti-D 219
- Preblud, S.R. 104
- Prentice, J.C. 357–8
- prescription drugs 358–60
- present value approach 37–9
- prevention 98–100
 versus cure 101, 107–9
- price change, effect on drug use 106–7
- price elasticity of demand 80, 112–14, 361, 380–81, 396
 cross-price elasticity 106–7
 excess burden of taxation and role of 121–2
 own-price elasticity 106, 122
- priority setting, use of CUAs 225–7, 237–41
- private costs 89, 91–2
- private goods 344
- private sector 12, 16, 125, 131
 cash transfers 117–19, 132
 cost differences with public sector 141
 and privatization 136–9
 rates of return 182
 and user fees 395–6
- private transfers 142–3, 389–90
- privatization 119, 136–9
- probability sampling 170
- probability value (*p*-value) 190, 196–8, 278
- proctosigmoidoscopy 78
- production function 33–7
- Program for Assertive Community Treatment (PACT) 141
- programs, checking effectiveness of 4–5
- property tax 124–7
- Propper, C. 345, 354, 357
- prospect theory 349–50
- prostate cancer 4

- prosthesis costs 48–50
- psoriasis 314
- psychiatric hospitals
 - deinstitutionalization 139–41
 - privatization 136–9
- psychiatric patients
 - case management programs 141–3
 - community care 139–41
 - valuing state expenditures 172–4
- psychogeriatric wards, use of restraints 305–7, 308
- public financed future health care spending
 - and MCF 135–6
- public goods 344
 - pure public goods 99, 341–2
- public participation in decision-making 240–41
- public policy domain 11
- public sector 99, 125, 130–32, 340
 - cost differences with private sector 141
 - cost shifting 119, 136–41, 142–3
 - and deinstitutionalization 139–41
 - and privatization 136–9
 - transfer payments 117–19
- public transfers 142–3, 389–90
- public–private partnerships 132
- pulmonary function costs/charges 85
- ‘pure public goods’ 99, 341–2
- ‘pure’ time preference rate 181, 184
- ‘quality adjusted life year’ (QALY)
 - and ageism 289–91
 - calculating 224–5
 - cost per QALY 217–21, 233–4
 - and DALYs 283–4
 - determining weights 282–3
 - equal weights 228–9, 283, 378–9
 - fixed price QALYS 423–4
 - gallstone treatments 17–18
 - group QALYs 387, 388, 392–5
 - in health profiles 269–70
 - and hepatitis B 254
 - incremental QALYs 276–7
 - league tables 218–19, 231–3, 243–4, 253–4
 - in neonatal intensive care programs 230–31
 - in Oregon plan 225–7, 237–41, 244
 - pricing 8, 10
 - and QoL 17, 47–8
 - role of weights 282
 - in total hip arthroplasty 241–3
 - unequal weights 290
 - US CEA Panel recommendations 223–4, 249
 - value by study type 323
 - weights as an externality 376–7
 - weights in CUA 228–9, 374–6
 - weights varying according to recipients 301–2
 - weights varying according to size of QALYs 300–301
 - and WTP 228
- quality of life (QoL)
 - and ARVs 436–7, 438
 - disabled people 286–7
 - elderly people 297–9, 305–7, 308
 - health and non-health measures 438
 - for same disease 277–8
 - and vision acuity 271–2, 274–7
 - see also* EuroQol
- Quality of Well-Being Scale (QWB) 224–6, 277
 - calculations with and without treatment 225
- quantity–frequency (Q–F) index 164–5, 175–6
- Rabin, R. 258–9
- radiology costs/charges 48–50, 85
- randomized controlled trials (RCTs) 15, 55–6, 150, 333, 369
 - advantages 158–9
 - as alphabetization 170
 - compared to difference-in-difference estimator 156–8
 - disadvantages 159–60
 - inclusion and exclusion criteria 166–7
 - practical problems of implementing 160
 - role in health care evaluations 160–61
 - ways to estimate true effects of interventions 157
- rank ordering 151–2, 225–9, 237
- rating scale (RS) 249–50, 255–6, 273–4, 277–8
 - compared to PTO 292–4
 - compared to SG and TTO 248, 266–70
 - converting into TTO 258
 - overview 254–5
 - statistical accuracy 250–52
- rationality 103, 181, 184, 201, 205, 256, 340, 358, 360
- rationing
 - Oregon 226, 239–40
 - by price 362, 365, 372–3
 - by waiting lists 355–8
 - by waiting time 353–5
- Ravens-Sieberer, U. 277
- Read, J.L. 267, 277
- ‘reasonable and customary charges’ 76–7
- Redelmeier, D.A. 273–4, 278, 415
- redistribution 223, 340–41, 378–9, 384
- reference case methodology 223–4, 253–4
- regular care (RC), hypertension 19–20, 154–6
- rehabilitation costs 48–50
- related treatments, combining for evaluation 150

- relative value units (RVUs) 69–70, 75–6
renal dialysis 218, 241–2, 248, 249–50, 251–2
resource neutrality 117, 120, 128, 134
resource-based relative value scale (RBRVS)
76–9
and Medicare charges 78
respiratory therapy costs/charges 85
revealed preference (RV) approach 164–5,
174–6, 199–201, 234–7, 239, 341, 388, 401,
403
applied to social decision makers 433–5
HIV/AIDS 426–8
pros and cons for social decision makers
435–6
use for pricing QALYS 332–4
revenue neutrality 122, 129–30, 134
Revicki, D.A. 56–7
ribavirin 222, 236
Rice, D.P. 141
Richardson, J. 267
Ried, W. 258
rigorous evaluation, advantages/disadvantages
23–6
riluzole 222, 236
risk aversion/neutrality 160, 163, 171, 228–9,
257, 266, 273–4, 279–80, 397
road fatalities 324–6
Robinson, L.A. 315
Robinson, S. 251–2
Rodgers, J.D. 389–90
Roebuck, C. 71, 72
Roehrborn, C.G. 4
Rosen, S. 360
Rosser, R. 253–4, 255, 266, 292
rubella vaccinations 104–5
ruptured intestine 227
Rush Foundation 420
Russell, L.B. 223, 249
Rwanda
male circumcision programs 416–17
MCF/social discount rate 128, 202
Ryan, M. 365–7, 371–2
Sabik, L.M. 240
Sachs, J.D. 204
Sackett, D.L. 248, 249, 253
sales tax 31, 68, 119, 124–5, 126–7, 129,
131–2
salmonellosis 227
sampling error
and *C/E* acceptability curves 195–9
and *C/E* ratios 191–3
methods for calculating confidence intervals
for *C/E* ratios 193–5
and statistical theory 188–90
Samuelson, P.A. 99, 344
Saudi Arabia, social discount rate 203
Scharff, R.L. 204–6
Schimmel, V.E. 75–6
schistosomiasis (bilharzias) control programs
98–100, 107–9
prevention versus cure 101
schizophrenia treatment regime 56–7, 207–8
school-based treatment programs
intestinal worms 130, 160, 168–70
tuberculin testing 219
Schwartz, M. 70
sectoral evaluation comparisons 16–17
seizure 76
selection bias 55–7, 83, 158–9, 160
Sen, A. 294–5, 300, 310
Senegal, MCF, social discount rate 128, 202
senior companion program (SCP) services
370
sensitivity analyses 223–4, 231, 236, 241, 253,
274, 391
setting range 187–8
and switching value technique 111–12
septicaemia 227
serious disease, cut-off ratio estimate
170–72
services, broad definitions 243
sexually transmitted infections (STIs) 50–53,
413, 422–3, 431–2
Shillcutt, S.D. 244
Shiroiwa, T. 325–6, 332, 333
short run cost curves 33–5
short run costs 32
sibutramine 222, 236
side effects of treatment 5, 14, 17–20, 41, 150,
207, 218, 252, 302, 358–60, 436–7
Siegel, C. 191–3, 207–8, 209
Siegel, R. 223
Sierra Leone, social discount rate 202
Singapore, social discount rate 203
Siraprasiri, T. 111–12
skewed distributions 20, 159–60
Skinner, J.S. 135–6, 137
small projects, evaluation of 16
Smith, P. 341, 353–5
smoking 112–13, 180, 185, 222, 232, 233, 236,
346–8
Snellen classification 271
social benefits 65, 76, 304–5, 380, 389
social costs
childhood immunization 103–6
drinking and driving 101–3
and private costs 89
social decision makers, revealed preferences
433–6

- social discount rate 211–12, 345, 435, 442
 - country estimates 201–4
- social marginal cost 91–3, 101
- social marginal utility 381–2, 384–5, 404
- social marketing programs 426–9
- social objectives 118, 310, 380, 383–5, 387, 388, 401, 433–4
- social optimality 12, 66, 91–4, 99–102, 104, 115–16, 345
- social perspective 12–13
- social production function for well-being (SPF-IL) 308
- social security benefits 132–5
- social services interventions 297–9, 310, 395
- social time preference rate (STPR) 182, 184, 345, 383
- social value 142, 211–12, 281–2, 307–9, 375, 378, 380–81, 389, 419
 - physician services 79–81
- socio-economic status, rationing by 354–5
- Solano, P. 361, 362
- Somalia, social discount rate 202
- Sonnenberg, F.A. 262
- South Africa
 - male circumcision 161, 165–7
 - MCF/social discount rate 128, 203
- South Korea
 - MCF/social discount rate 130, 203
 - price of QALYS 325–6
- South/South-East Asia, HIV/AIDS 412
- Spain, MCF/social discount rate 130, 203
- Spearman rank correlation coefficient 270
- speed limits 334–6
- Squire, L. 182, 184, 383, 384, 388–9, 396, 399, 401, 429
- Sri Lanka, social discount rate 202
- Stabilized Response Treatment Intervention (SRTI) 207–8
- standard error 189–90, 193, 200–201, 210–12, 251
- standard gamble (SG) 254–8
 - compared to RS and TTO 266–70, 415
 - compared to TTO 271–4
 - and prospect theory 349–50
 - statistical accuracy 250–52
 - total hip arthroplasty 241–3
- Starmer, C. 256
- Stason, W.B. 150, 185, 186–7, 252
- stated preferences 177, 292, 438, 441
- statistical theory and sampling error 188–90
- step-down accounting 62–3, 84–5
- Stern, S.H. 34–7, 48–50
- Stillwaggon, E. 414
- stool guaiac protocol 3–4, 21–3
- Stubblebine, C. 89
- stunting, education effects 110–11
- Sub-Saharan Africa (SSA)
 - CCT programs 397, 400
 - HIV/AIDS 166–7, 304–5, 412, 413–14
- subgroup differences 160
- subsidies 69, 113, 168, 177, 360, 387, 395, 423, 426–9, 440
- substance abuse treatment programs
 - advantages of cost standardization 71–3
 - client costs 80–82
- substitutes 95–8, 106–7, 112–13
- Sudan, MCF 128
- sunk costs 61
- surgical wards, opportunity costs 44–5
- Swaziland, MCF 128
- Sweden
 - alcohol study 39, 57–8
 - MCF/social discount rate 130, 204
- switching values 102–3, 111–12, 231, 239
- threshold values as 90–91
- Switzerland, MCF/social discount rate 130, 204
- syphilis 314
- Syria, social discount rate 202
- Taiwan, price of QALYS 325–6
- Tamil Nadu, HIV-prevention interventions 50–53
- Tanzania
 - condom social marketing programs 426–8
 - female education 424–5
 - MCF/social discount rate 128, 202
 - voluntary counselling and HIV testing 431–2
- Tarride, J.-E. 14–17
- taxane ovarian 222, 236
- taxation
 - administrative costs 144–5, 378–9, 398
 - alcohol 93, 95–8
 - cigarettes 119–21
 - excess burden 116, 117–23, 129, 138–9, 141, 163–4, 401
 - by income group 135–7
 - incorporating into tax cost calculations 133–5
 - marginal excess burden 124
 - rates relationship with excess burden 125–7, 143–4
 - revenue neutrality 122, 129–30, 134
 - and social cost of drinking and driving 101–3
- taxine breast 222, 236
- Taxol 180
- technological progress 186–7

- technology appraisals 10, 220–22, 233–7, 388
- Temin, P. 358–60, 373
- temozolamide 222, 236
- temporomandibular joints 226
- Tengs, T. 277–8, 414–15
- Thailand
 social discount rate 203
 vaccination programs 112
 WTP per QALY 325
- Thaler, R. 360
- Thavorncharoensap, M. 324–5, 332
- Thayer, M.A. 370
- therapeutic communities, costs by 72
- thiazide diuretics 360
- Thompson, M.S. 391–2
- thoracostomy 78
- threshold value 9–10, 14
 country estimates 325–6
 HIV/AIDS 438–40
 live donor kidney transplants 46–8
 NICE program 233–7
 Oregon Plan 244
 as range of values 220–22
 as switching values 90–91
 use of price 9–10, 14, 90–91
- thyroid screening 219
- time costs 47, 81–2, 84, 321
 rationing by 353–8
 speed limits 334–6
 use of wage rate to value 46, 81, 200, 335, 353–5, 368, 370–71, 424–6
- time preference 266, 270, 307–8, 355, 357–8
- time preference rates 181–2, 188, 201, 205, 345, 383
 ‘pure’ time preference rate 181, 184
- time trade-off (TTO) model 254–5, 277, 292, 307–8, 324, 349–50, 414–15
 compared to RS and SG 266–70
 compared to SG 271–4
 duration as a separate consideration 248
 and EuroQol 258–62
 and HYE 257–8
 and prospect theory 349–50
 statistical accuracy 250–52
- time-consistency/inconsistency problem 183–4, 205, 346
- Togo, MCF/social discount rate 128, 202
- Tokelau Island, female life expectancy 285
- topacetan 222, 236
- topical hydrocortisone 358–60
- Torrance, G.W. 218–19, 230, 248, 249, 250–51, 252, 253, 257, 267, 274, 277
- total hip arthroplasty (THA) 232, 241–3
- Towers, I. 257
- Towse, A. 234
- transfer payments
 cash transfers 80–81, 119, 129, 132–4, 145, 223, 299, 351–2, 390
 CCTs 379, 389, 397–400, 405, 421–2
 in-kind transfers 80–81, 82, 351–2, 389–91, 444
 and MCF 117–19, 124, 129, 132–5
 private transfers 142–3, 389–90
 and privatization 136–8
 public transfers 142–3, 389–90
- trastuzumab 222, 236
- travel cost method 342–4
 mobile breast cancer screening 367–9
 switching drugs 358–60
- treatments (procedures), advantages/
 disadvantages of concentrating on 16–17
- Trinidad and Tobago, social discount rate 203
- Trommlerova, S.K. 24
- Troms, ambulance helicopter service 376
- trypanosomiasis (sleeping sickness) 302–3
- Tsuchiya, A. 289–90, 291
- tuberculosis (TB) 227, 285
- Tulloch, G. 228
- Tunisia, social discount rate 203
- Turkey
 hospital construction 401, 403
 social discount rate 203
- Tversky, A. 350
- two-stage evaluation process 20
- Ubel, P.A. 292–4, 387
- Uganda
 bednet use 352
 DALY losses at age of death 287–8
 male circumcision 161
 MCF/social discount rate 128, 202
 sleeping sickness treatments 302–4
- UK
 health care evaluation practice 9–10, 15, 130–32
 league table of interventions 231–3
 MCF/social discount rate 130, 203
 nursing home versus hospital care 363–5
 QALY rankings compared to US 243–4
 rationing 353–8
 social services interventions 297–9
 valuing a QALY 325–6, 333
 weighting system 384
 see also National Health Service (NHS);
 National Institute for Health and
 Clinical Excellence (NICE)
- uncertainty
 applications 207–10
 CM evaluations 211
 and economic evaluation 180–81

- NICE specifications 234, 388
- problems 211
- and sampling error 188–99
- techniques for dealing with 111–12
- use of SG 256
- unidimensional treatments 228–9, 245
- Uniform Facility Data Set (1997) 361
- United Nations
 - Declaration of Human Rights 286
 - UNAIDS 50, 304, 411–12, 426
 - UNDP 299
- Uruguay, social discount rate 203
- US
 - antiretroviral drugs for elderly 436–8
 - community psychiatric care 139–41
 - costing and evaluating DRG categories 75–6
 - federal MCF estimates 123–4
 - hospital costs 34–7, 48–50, 64
 - MCF/social discount rate 130, 204
 - price of QALYS 325–6
 - privatization of non-federal general hospitals 137–9
 - public financing of future health care spending 135–6
 - QALY rankings compared to UK 243–4
 - state expenditures on mental health inpatient episodes 172–4
 - state MCF estimates 124–5
 - transfer payments 132–5
 - valuing physician services 76–81
- US Department of Health and Human Services 227
- US Public Health Service, Panel on Cost-Effectiveness in Health and Medicine 188, 223–4, 227, 231, 249, 253
- user fees 68–9, 117–19, 231, 343, 367, 381
 - Peru 395–7, 401–2
- Usher, D. 127–9, 130
- utilities measurement 5, 8
 - analyst measurement 254–5
 - applications 265–77
 - category rating scale method 255–6
 - EuroQol instrument 258–62
 - health state duration as a separate consideration 248, 277
 - Markov modelling instrument 262–5
 - measurement stages 247–8
 - personal judgement by analyst 252–3
 - problems 277–8
 - reference to literature 253–4
 - SG method 256–7
 - statistical accuracy of methods 250–52
 - use of TTO 257–8
 - whose utility values to use 248–50
- utility estimates survey 266
- utility maximization 13, 41, 64–6, 129, 162–3, 219, 294–5, 317–18, 345, 426, 431, 435–6
- utility of income, as cut-off ratio 162–3, 170–72, 317–18
- vaginal delivery 76
- Vaillant, G.E. 174
- value of a statistical life (VSL) 313, 316, 322–4
 - age-group specific 331
 - comparison using cross-sections with cohort analysis 331
 - Conley model 319–20
 - estimating in developing countries 430–31
 - Linnerooth model 317–19
 - older adults 329–32, 336–7
 - pros and cons for HIV/AIDS 432–3
 - use for HIV/AIDS 429–32
 - and worker occupation choices 327–9, 350–51
- valve replacement for aortic stenosis 232
- Van Der Pol, M.M. 210–11
- van der Tak, H. 182, 184, 383, 384, 388–9, 396, 399, 401, 429
- Van Hout, B.A. 185, 186
- variable costs 32, 33–6, 48–51, 53–4
 - average variable costs 34–5
- varicose veins 44–5
- Venezuela, social discount rate 203
- vertical equity 281–2, 283–4
- Veteran's Administration, US 358
- Vinod, H. 7
- Viscusi, W.K. 180, 187, 199–201, 327–9, 330–32, 336–7, 351
- vision acuity utilities 271–2
- Visual Analogue Scale (VAS) 255
- voluntary counselling and testing (VCT), HIV/AIDS 431–2
- Von Neuman, T. 256
- wage rate, in time valuation 46, 81, 200, 335, 353–5, 368, 370–71, 368, 424–6
- Wagstaff, A. 281, 282–3
- waiting lists 355–8
- waiting times 353–5
- Walter, S.D. 14, 193–5
- Walters, M. 125–7, 128, 145, 399
- wasting, educational effects 110–11
- Weiers, R.M. 188, 357
- Weight Watchers (WW) 205, 206
- Weimer, C. 98–101, 107–9
- Weimer, D.L. 346–7
- Weinstein, M.C. 150, 151–3, 155, 172, 185, 186–7, 219, 223, 226, 244, 249, 252–3
- Weintraub, W.S. 84, 85
- Weisbrod, B.A. 104, 317, 326–7

- welfare economics 13, 27–8, 340–41
welfarism 294, 299
Western Europe, HIV/AIDS 412
White, C.C. 104
Whittington, D. 439
Wikipedia 129, 130
Wildasin, D.E. 132–5, 143–4
Willan, A.R. 193
Williams, A. 290, 374
Williams, J. 98
willingness to accept (WTA)
 difference with WTP and effectiveness of
 interventions 351–2
 difference with WTP in practice 350–51,
 370
 difference with WTP in theory 348–50
willingness to pay (WTP)
 and ability to pay 334
 applications 358–69
 compensation tests and economic efficiency
 340–41
 and consumer sovereignty 345–8
 course delivery modes 177
 different countries 325–6
 different diseases 324–5
 direct evidence of appropriateness 358–60
 distinctions with WTA 348–52
 drug treatment 314
 externalities 376–7
 HIV/AIDS vaccines 439–40
 implicit estimate of appropriateness 360
 market-based approach 426–9
 median valuations 323, 338
 positive relation to QALYs 228
 problems 370–71
 and public goods 344
 and rationing by time 352–8
 relation to income 320, 391–2
 relation with human capital approach
 317–20
 risk reduction 330–32
 valuation methods 341–4
 versions of 322
 and waiting times 353–5
Wilms' tumor 227
women
 education and HIV 161, 424–5
 unavoidable costs of alcohol 39, 57–8
worksite programs, hypertension care 19–20,
153–6, 180
World Bank 169–70, 182, 288, 383, 384
 Global Burden of Disease study 287, 288–9
 World Development Report 303
World Health Organization (WHO) 287, 416,
417
Worrall, J. 160–61
X-rays, labour costs 83–4
years of life lived with disability (YLD) 304–5
years of life lost (YLL) 304–5
Yu, X. 112–13
Yugoslavia, social discount rate 203
Zaire, social discount rate 202
Zambia, MCF/social discount rate 128, 202
zanamavir 222, 236
Zarkin, G.A. 314, 344, 376, 382
zidovudine 233, 242, 262–5
Zimbabwe, MCF/social discount rate 128, 202